High performance plasma amyloid-β biomarkers for Alzheimer’s disease

By A. Nakamura, Naoki Kaneko, V. Villemagne, Takashi Kato, J. Doecke, V. Doré, C. Fowler, Qiao-Xin Li, R. Martins, C. Rowe and 10 more. Nature, 2018

1,471 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018, neutral): “Plasma Aβ measures now show promise [202,203].”
Hallmarks of neurodegenerative diseases. (2023, neutral): “71,72 Additional markers that reﬂect amyloid build-up in the brain are CSF and plasma phosphorylated forms of tau, reﬂecting a link be-tweenbothpathologicalprocessesinAD.”
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis (2019, methodology): “The ratio of plasma Aβ42 to Aβ40, as measured by high-precision assays, has previously been shown by our group and others to have a high correspondence to brain amyloidosis.(12,13) Plasma Aβ42/Aβ40 may have higher concordance with amyloidosis than plasma Aβ42 and Aβ40 separately because this ratio m”
Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group (2021, background): “Although promising, they require further standardization and validation before they can be broadly regarded as secure biomarker evidence of AD pathology (A+T+) 45,81 .”